Compare F.N.B. Corporation Common Stock (FNB) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs McKesson Corporation — how do they compare? F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.03B), while McKesson Corporation trades at $986 (market cap $113.86B). The key difference: McKesson Corporation is far larger — about 18.9× F.N.B. Corporation Common Stock's market cap, and F.N.B. Corporation Common Stock pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and McKesson Corporation for 74 Days on average.
| FNB | MCK | |
|---|---|---|
Market Cap | $6.03B | $113.86B |
Volume | 7,117,178 | 767,917 |
Sector | Financials | Health |
52-Week High | $19.49 | $995.69 |
52-Week Low | $14.65 | $725.17 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $10.52B | $120.40B |
Dividend Yield | 3.07% | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
MCK trades at $961.88, up 0.64% today, showing strong momentum with three consecutive earnings beats and a bullish technical outlook. The stock benefits from robust revenue growth reaching $359.1B in 2025 and positive sentiment from the recent CVS Health partnership extension through 2032. Analyst consensus remains strongly bullish with 81% buy ratings and a $956.43 price target, though the current price slightly exceeds this target.
MCK presents a compelling investment case with solid fundamentals and growth trajectory, though investors should monitor margin pressures and competitive dynamics. The company's strong cash flow generation and institutional support provide stability, while technical indicators suggest near-term resistance around $967-$978 levels could limit immediate upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
